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Summary objective Parasites may recur asymptomatically after initial clearance by antimalarial treatment.
Current guidelines recommend treatment only when patients develop symptoms or at the end of follow-
up. We wanted to assess prospectively the probability of becoming symptomatic and the risks of this
practice.
methods We analysed data collected in 13 trials of uncomplicated paediatric malaria conducted in
eight sub-Saharan African countries. These studies followed all cases of post-treatment asymptomatic
parasitaemia until they developed symptoms or to the end of the 28-day follow-up period, at which time
parasite genotypes were compared to pre-treatment isolates to distinguish between recrudescences and
new infections.
results There were 425 asymptomatic recurrences after 2576 treatments with either chloroquine,
sulfadoxine⁄pyrimethamine or amodiaquine, of which 225 occurred by day 14 and 200 between day 15
and day 28. By day 28, 42% developed fever (median time to fever = 5 days) and 30% remained
parasitaemic but afebrile, while 23% cleared their parasites (outcome unknown in 4%). Young age,
parasitaemia ‡500 parasites⁄ll; onset of parasitaemia after day 14, and treatment with amodiaquine
were the main variables associated with higher risk of developing fever.
conclusion In areas of moderate to intense transmission, asymptomatic recurrences of malaria after
treatment carry a substantial risk of becoming ill within a few days and should be treated as discovered.
Young children are at higher risk. The higher risk carried by cases occurring in the second half of
follow-up may be explained by falling residual drug levels.
keywords malaria, malaria treatment, asymptomatic parasitaemia
Introduction 1
Asymptomatic parasitaemia may occur after initial clear-
ance of parasites after antimalarial treatment. The clinical
relevance of such episodes is unclear and until recently they
were considered as treatment failures requiring rescue
treatment only when accompanied by fever (WHO 1996).
While the latest WHO protocol (WHO 2003) now
considers these episodes as (late) parasitological failures
(LPF), it recommends treatment only when they become
symptomatic, or, if they remain asymptomatic, at the end
of follow-up.
In order to assess if this practice is justiﬁed, and if not
offering rescue treatment immediately unduly exposes
study participants to a potential risk of disease progression,
we assessed the occurrence and outcome of post-treatment
recurrent asymptomatic parasitaemia in a large collection
of studies (13 trials enrolling 2576 children with uncom-
plicated falciparum malaria in eight African countries
during 2001–2004, comprising a total of 24 treatment
arms with chloroquine (CQ), sulfadoxine⁄pyrimethamine
(SP), or amodiaquine (AQ); reported in Guthmann et al.
2006).
Methods
Asymptomatic recurrent parasitaemia is deﬁned based on
blood smear results as a case of initial clearance of
parasites by treatment with subsequent (i.e. any time
before day 28) recurrence of parasites in the absence of
fever. The study population were children aged 5–59
months with acute uncomplicated falciparum malaria
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trials done in eight African countries during 2001–2004
(the methods and results of these studies are reported in
Guthmann et al. 2006). Asymptomatic recurrent parasi-
taemias occurring post-treatment were recorded but not
treated and followed until the end of follow-up (day 28)
and treated as they developed symptoms or on day 28 if
still parasitaemic according to the 2003 WHO protocol
(WHO 2003).
We observed the evolution of these cases for as long as
they were on study, and classiﬁed children based on
whether they (i) developed fever [late treatment failures
(LTF)], (ii) remained parasitaemic and asymptomatic up to
the end of follow-up on day 28 [late parasitological failures
(LPF)], or (iii) cleared parasites ‘spontaneously’ [adequate
clinical and parasitological response (ACPR)].
In all cases occurring on days 15–28 (hereinafter ‘post-
d14’), blood spots on ﬁlter-paper were taken either when
they had become febrile or at the end of follow-up. Parasite
DNA extracted was compared to the pre-treatment sample
by polymerase chain reaction (PCR) with regards to the
merozoite surface protein msp1 and msp2, and recurrences
were classiﬁed as new or recrudescent infections. Recur-
rences occurring before or on day 14 (hereinafter, ‘by d14’)
were assumed to be recrudescences and thus not geno-
typed.
We performed univariate Kaplan–Meier survival analy-
ses of the risk of developing fever stratiﬁed by treatment,
sex, age, day and level of parasitaemia at recurrence and
type of infection (new or recurrent). All comparisons were
done using the log-rank test. Three groups were consid-
ered: (i) all 425 patients with asymptomatic recurrent
parasites; (ii) the 180 patients who became LTF; (iii) the
153 who became LTF and could be classed as either new or
recurrent infections by PCR.
Multivariate analyses were conducted by descending
manual modelling using a likelihood ratio test to verify the
signiﬁcance of loosing information in the model as a
consequence of the deletion of a variable. A Cox propor-
tional hazard ratio model was used to study risk (‘hazard’)
of fever. The proportional hazard assumptions of the Cox
model were veriﬁed for groups (ii) and (iii) above but not
(i). For this group (all 425 patients) we used a logistic
model in which, however, the time under observation
could not be used because it was redundant with the risk of
fever (signiﬁcant Hosmer and Lemeshow goodness-of-ﬁt
test.) Data were analysed using stata 8.2 (Stata Corp.,
College Station, TX, USA) and sas System 9.1.3 (SAS
Institute, Cary, NC, USA).
Results
The summary results are in Table 1. Of the 2576 patients
included in these studies, 593 received CQ, 989 SP and 994
AQ (Guthmann et al. 2006). The median 28-day risk of
failure were 81% for CQ, 25% for SP and 17% for AQ. In
this population, we detected 425 episodes of asymptomatic
parasitaemia following initial clearance after treatment
with CQ (n = 141, 24% of the patients enrolled), SP
(n = 170, 17%) or AQ (n = 114, 11%). The occurrence of
asymptomatic parasitaemia paralleled success rates and
was lowest after AQ and highest for CQ. Of these 425
cases, 180 (42%) developed symptoms within the 28-day
follow-up; 52 cases (37% of asymptomatic parasitaemias)
with CQ, 65 (38%) with SP and 63 (55%) with AQ.
Overall, 225 episodes (53%) occurred by d14 and were
followed for a median of 14 days [interquartile range
(IQR): 7–14], and 200 (47%) occurred post-d14 and were
followed for a median of 7 days (IQR: 4–7). Parasite
counts were signiﬁcantly higher (Mann–Whitney,
P = 0.01) in the post-d14 episodes [geometric mean, 95%
conﬁdence intervals: = 781 (95% CI 568–1073) post-d14
vs. 276 (209–363) by d14] (Table 2).
By day 28, 17 patients (4.0%) were lost to follow-up or
excluded, 99 (23.3%) had cleared their parasitaemia
(ACPR), 129 (30.3%) remained positive but afebrile (LPF)
and 180 (42.4%) developed fever within the 28-day
follow-up (LTF). Of the latter, nine developed fever by day
14 and were considered a recrudescence without PCR
genotyping, and 171 developed fever post-d14 and were
genotyped at the time of reappearance of symptoms or on
day 28 if LPF. PCR was resolved for 144 cases (76
Table 1 Treatment outcome and occurrence of asymptomatic parasitaemia and symptoms by drug
Drugs Enrolled
D28 risk of
failure, median
(range)
Asymptomatic
recurrence,
n (%)
Became febrile
by day 28,
n (%)
Time to fever
(days), median
(IQR)
CQ 593 81 (24–87) 141 (24) 52 (37) 5 (2–7)
SP 989 25 (7–41) 170 (17) 65 (38) 7 (3–8)
AQ 994 17 (5–28) 114 (11) 63 (55) 3 (2–5)
Total 2576 425 (16) 180 (42) 5 (2–7)
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(eight missing sample, three with no DNA, 16 not
interpretable). Therefore, in total we had 153 cases which
were ascribed to either a recrudescence (n = 85) or a new
infection (n = 68) (Figure 1).
Overall, 50% of fevers occurred within 5 days (Table 1),
84% within 7 days and 90% within 10 days of detection
of parasites (Figure 2a). Time to fever by drug, time of
appearance and level of parasitaemia at detection are
presented in Figure 2b–d. The risk of fever varied widely
across study sites (from 7% in Chad to 74% in Kuito,
Angola), and even within the same country (10–68% in
Sierra Leone) (data not shown).
The results of the univariate Kaplan–Meier analysis are
in Table 3. For all the 425 patients with recurrent parasites
the risk of developing fever and thus becoming a LTF was
signiﬁcantly associated with age, treatment, level of para-
sitaemia at detection and type of infection (all P < 0.001)
and just reaching signiﬁcance levels for the day of discovery
of the asymptomatic parasitaemia (P = 0.05). Considering
the 180 patients who became LTF, risk of fever was
signiﬁcantly associated with sex (shorter in male), treat-
ment, days of recurrent asymptomatic parasitaemia
(shorter if post-day 15), level of parasitaemia (shorter if
>500 parasites⁄ll) and type of infection (shorter if a new
infection). There was no association with age. This remains
true when restricting the model to the 153 patients who
could be assigned to a new or reinfection.
In the logistic model used for all 425 patients the
independent variables signiﬁcantly associated with risk of
LTF were age, treatment and level of parasitaemia at
detection (Table 4). In this model without time under
observation the there was no evidence of lack of ﬁt
(Hosmer and Lemeshow goodness of ﬁt P = 0.31). Here
the risk of fever was signiﬁcantly higher (i) with AQ than
both SP and CQ (P = 0.007, not shown); (ii) for parasi-
taemias ‡500⁄ll; and (iii) for ages >24 months than
6–12 month olds. We found no interaction between any
variables.
In the Cox model (Table 5) which could be applied to
the 180 patients who developed fever and the 153 who
were also assigned to a new or recrudescent infection,
treatment, day and level of parasitaemia remained associ-
ated with risk of fever. The difference in parasitaemia
between new infections and recrudescences was statisti-
cally non-signiﬁcant when they were asymptomatic when
ﬁrst detected [geometric mean (95% CI) 799.4 (460.5–
1387.8) vs. 648.9 (395.7–1064.1), P = 0.56] and when
Asymptomatic recurrences 425
Became symptomatic 180 (42%)
By day 14 9 (5%) 171 (95%) Post day 14
Type of infection Assigned by PCR Total
Recrudescence 9  76 (44%) Resolved: 85 (47%)
New infection 68 (40%) 144 (84%) 68 (38%)
Unresolved 27 (16%) 27 (15%)
By drug Total
CQ 8 (15%) 5 (10%) 26 (50%) 13 (25%) 52
SP 1 (1.5) 14 (21.5) 32 (49%) 18 (28%) 65
AQ 0 (13%) 18 (28%) 37 (59%) 63
Recrudescence
New
Infection Assigned Unresolved
Figure 1 Genotyping of isolates at the time
of fever.
Table 2 Asymptomatic parasitaemias by the time of recurrence (crude outcomes prior to PCR genotyping)
Recurrent
parasitaemia
occurring n (%)
Parasite counts
geometric mean
(95% CI)
Follow-up
(days), median
(IQR)
Outcome by day 28, n (%)
Cleared
parasites
(ACPR)
Parasites no
fever (LPF)
Parasites and
fever (LTF) Not evaluable
By day 14 225 (53) 276 (209–363) 14 (7–14) 62 (28) 52 (23) 96 (46) 15 (7)
Post day 14 200 (47) 781 (568–1073) 7 (4–7) 37 (18) 77 (33) 84 (42) 2 (1)
All 425 (100) 450 (363–557) 7 (5–14) 99 (23.3) 129 (30.3) 180 (42.4) 17 (4)
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27161.1 (18153.4–40638.4) vs. 21785.1 (15077.6–
31476.4), P = 0.34] (Table 6 2 ).
Discussion
Case management and treatment guidelines
Our analysis is based on a large database of non-compar-
ative studies of paediatric malaria treated with monother-
apies of variable efﬁcacies, conducted in areas of moderate
to intense malaria transmission. These data allow three
main sets of conclusions. In these settings, reappearance of
parasites after initial clearance carries a considerable risk
for the patient of becoming ill within a few days (in 50% of
cases within 5 days.) Thus, we conclude that the risk of
disease progression justiﬁes treating parasitaemia occurring
during follow-up as detected.
WHO (2005) guidelines now recognize the risk of
persistent parasitaemia post-treatment (patients who never
clear parasites but become asymptomatic, as opposed to
these cases in which parasites were cleared initially but
reappear later during follow-up not accompanied by
symptoms) and state that they should be considered as
failures and ‘be treated with drugs or combinations that are
more effective than those administered on day 0, in order
to avoid delayed manifestation of clinical signs and
symptoms’ The data presented here call for also asymp-
tomatic parasitological recurrences to be treated as
detected.
Weekly follow-up visits as per the WHO protocol
appear to be an effective means of detecting asymptomatic
parasitaemias, but ensuring optimal attendance to follow-
up visits and minimizing losses to follow-up are crucial to
capture these cases early. After discounting the 14 exclu-
sions, in these studies the risk for a patient of having
neither parasites nor symptoms at the end of the 4-week
follow-up (ACPR) was 0.24; of having persisting parasites
but no symptoms (LPF), 0.31; and of having parasites and
developing symptoms (LTF), 0.44. Comparisons with
other datasets are difﬁcult, as the outcome of asympto-
matic parasitaemia is not systematically investigated. In a
trial with SP in Tanzania (Mutabingwa et al. 2001), of the
140 evaluable patients who cleared symptoms but not
parasites, these risks were: ACPR = 0.19, LPF = 0.15 and
LTF = 0.66. For comparison in survey studies, the risk of
0
S
u
r
v
i
v
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
0.8
1
0.6
0.4
0.2
10
95% Pointwise confidence limits for survivorship
0 2.5 7.5 12.5 5
Time to fever
0
S
u
r
v
i
v
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
0.8
1
0.6
0.4
0.2
95% Pointwise confidence limits for survivorship
10 0 2.5 7.5 12.5 5
Time to fever
AQ
CQ
SP
0
S
u
r
v
i
v
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y 0.8
1
0.6
0.4
0.2
95% Pointwise confidence limits for survivorship
< 500
>= 500
Time to fever
10 0 2.5 7.5 12.5 5
By day 14
Post day 14
0
S
u
r
v
i
v
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y 0.8
1
0.6
0.4
0.2
95% Pointwise confidence limits for survivorship
Time to fever
10 0 2.5 7.5 12.5 5
(a) (b)
(c) (d)
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with no parasites and no symptoms was 0.05 within
30 days in Gabon (Missinou et al. 2003) and 0.11 within
1 year in Uganda Njama-Meya et al. 2004). In our study,
we may have underestimated the risk of clinical progres-
sion to a LTF because of the short duration of follow-up
with the 28-day study and because we cannot rule out the
use of antimalarials in the cases subsequently found with
no parasites. We believe that the occurrence of these
‘spontaneous conversions’ does not justify complacency in
case management.
The risk of LTF after initial clearance varied with these
mono-therapies (hence related parasite susceptibility at the
study site.) With more effective treatments, like the
currently recommended combinations (WHO 2006), one
would expect fewer such cases. Here, on aggregate all drugs
tested had failure rates >10%, a level at which the WHO
now recommends considering an alternative treatment.
Risk factors for LTF after an asymptomatic recurrence
Both the univariate analysis and the logistic model concur
in pointing out treatment with AQ, parasitaemia ‡500⁄ll
and detected post-d14 as carrying a greater risk of
developing fever and LTF. When considering all patients,
young age was at higher risk (with an apparent linear trend
Table 4 Logistic regression model of risk of fever
Parameter
Risk of fever
425 patients with recurrent asymptomatic parasitaemia
Estimate 95% Conﬁdence limits P-value
Treatments
SP 1
AQ 1.87 1.13 3.09 0.01
CQ 0.91 0.56 1.47 0.70
Level of parasitaemia at detection
<500 1
‡500 1.52 1.01 2.30 0.05
Age
6–£12 months 1
>12–£24 months 0.80 0.45 1.41 0.43
>24–£36 months 0.50 0.27 0.90 0.02
>36–£42 months 0.30 0.12 0.80 0.02
>42–£59 months 0.22 0.11 0.45 <0.0001
Hosmer and Lemeshow goodness-of-ﬁt test P = 0.31
Table 5 Cox proportional hazard ratio model of time to fever
Parameter
Time to fever
180 patients who became LTF
Time to fever
153 patients who became LTF and were assigned to
new or recrudescent infection
Hazard ratio
95% Hazard
ratio conﬁdence
limits P-value Hazard ratio
95% hazard
ratio conﬁdence
limits P-value
Treatment
SP 1 1
AQ 1.60 1.11 2.30 0.01 1.69 1.14 2.51 0.01
CQ 1.06 0.72 1.55 0.78 1.22 0.80 1.89 0.36
Day of recurrent parasitaemia
By day 14 1 0.05 1 0.02
Post day 14 1.40 0.99 1.97 1.57 1.07 2.29
Level of parasitaemia the day of reappearance
<500 1 0.003 1 0.02
>=500 1.57 1.16 2.12 1.47 1.07 2.04
Tropical Medicine and International Health volume 13 no 1 pp 83–90 january 2008
P. Olliaro et al. Post-treatment asymptomatic malaria parasitaemia
88 ª 2008 Blackwell Publishing Ltdin this age-range 6–59 months), while age was unimpor-
tant for those who did become LTF. This shows that
immunity builds up relatively early in life in these areas of
moderate to intense transmission, and that, for those who
do become symptomatic, the pre-patent period is largely
determined by the treatment given and not by age. Of the
three monotherapies used, patients on AQ were more likely
to become symptomatic and to do so sooner than CQ and
SP. The level of parasitaemia at which new and recrudes-
cent infections are detected and become symptomatic is
similar, but new infections carry a higher risk of pro-
gressing to symptomatic disease (in the univariate
analysis).
These observations are intriguing and elicit a number of
hypotheses with respect to parasite dynamics, para-
site⁄host interaction and drug disposition and effects. To
this effect we could not identify in the literature similar
studies documenting prospectively the pre-patent period of
malaria infections for comparison. Further studies will be
needed to substantiate possible explanations.
Drug pharmacokinetics and pharmacodynamics
Declining drug levels with time explain why recurrent
parasitaemias became symptomatic sooner when they
occurred in the second part of follow-up (post-d14). Drug
pharmacokinetics and pharmacodynamics may also help
account for and when they were due to a new infection.
There were differences between drugs. Time to fever was
signiﬁcantly shorter (i) for asymptomatic parasitaemias
occurring post-d14 when the treatment was AQ or SP but
not CQ; and (ii) for new infections when the treatment
was SP but not AQ or CQ. In addition, time to fever was
also longer with SP and CQ than AQ, but this should be
considered with caution as these were not direct com-
parisons.
An antimalarial drug’s post-treatment effect is likely to
depend upon the time during which plasma levels remain
above inhibitory concentrations (which vary with the levels
of parasite susceptibility in the different areas). This time is
related to the drug’s residence time in the organism but also
to the shape of the concentration-time curve. Despite
decades of use, there are still uncertainties over the
disposition of antimalarial drugs. It is outside the scope of
this article to discuss these differences, but it appears from
these data that plasma concentrations will fall below
inhibitory levels earlier for AQ than SP.
Higher parasite replication rates occur in the latter part
of follow-up after plasma levels had fallen below the
effective concentration necessary to inhibit parasite growth
(White & Pongtavornpinyo 2003). Unlike pre-existing
parasites, the parasites sustaining a new infection had not
been exposed to the drug at inhibitory levels, which could
provide an alternative explanation to the observation that
new infections manifest themselves sooner than recrudes-
cent infections. A limitation of this study is the absence of
drug levels measured in particular at the time of the
asymptomatic recurrence and fever. While generated with
single-agent treatments, these data are relevant to the
current use of these drugs (notably AQ and SP) in
combination as they are the longer-lived component of
artemisinin-based combinations (ACTs).
Conclusions
Post-treatment asymptomatic parasitaemia is associated
with a high risk of developing symptoms within 5–10 days;
whether due to a recrudescent or new infection, treatment
should not be postponed. The risk is highest early in life
and decreases as children grow older. Patients with
parasitaemias occurring post-d14 and ‡500⁄ll are at
higher risk. Differences between drugs are likely due to
their pharmacokinetic characteristics; amodiaquine carries
a higher risk.
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Table 6 Type of infection (as per PCR genotyping) in patients
who became symptomatic by time of occurrence of asymptomatic
parasitaemia (n = 153)
Outcome
Asymptomatic recurrence
All By day 14 Post day 14
Recrudescences
By day 14 9 0 9
Post day 14 45 31 76
All 54 31 85
New infections
Post day 14 26 42 68
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